Datamonitor Healthcare Ulcerative Colitis KOL Interviews
Datamonitor Healthcare Ulcerative Colitis KOL Interviews
$599.00
Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.
Author: Datamonitor Healthcare
Publisher: Biomedtracker
- Highlights
- Description
Highlights
- “So, for the biologics you have two broad choices right now for UC. You have vedolizumab [TKPYY], an antiintegrin alpha 4- beta-7 or you have an anti-TNF and you know, infliximab [JNJ] is actually the biologic that has been approved the longest for UC, but we also have adalimumab [ABBV] and golimumab [JNJ]. ”
- “The problem with all the protein-based biologics is that they are tricky to use because they are potentially immunogenic and so there is, built into the protein-based biologics, an inherent loss of response rate. ”
Overview
Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC. The specific drugs discussed include alicaforsen, Entyvio / vedolizumab [TKPYY], etrolizumab [RHHBF], filgotinib [GILD], Humira / adalimumab [ABBV], Inflectra / infliximab biosimilar, LT-02 [NSRGY], Ozanimod [CELG], Remicade / infliximab [JNJ], Simponi (SQ) / golimumab [JNJ], Stelara / ustekinumab [JNJ] and Xeljanz / tofacitinib [PFE]. The two interviews were combined into a single report.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the